Partnerships

Swedish Orphan Biovitrum AB

Biogen Idec and Swedish Orphan Biovitrum (SOBI) of Sweden have a strategic alliance to jointly develop and commercialize rFIXFc as a treatment for hemophilia B and rFVIIIFc for hemophilia A.

SOBI is a leading European specialty pharmaceutical company focused on providing and developing specialty pharmaceuticals for patients with rare diseases and significant medical needs.

---

For more information:

Swedish Orphan Biovitrum AB (publ)

SE-112 76 Stockholm

Sweden

Telephone: +46(0)8 697 20 00

Email: mail.se@sobi.com

www.sobi.com